Inhibitor Therapeutics (INTI) Interest Coverage Ratio (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Interest Coverage Ratio came in at 3.48 in Q1 2026, up 94.84% YoY from 1.79 in Q1 2025, and up 97.24% on a QoQ basis from 125.82 in Q4 2025.
Inhibitor Therapeutics (INTI) Interest Coverage Ratio (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 14 years of Interest Coverage Ratio data on file, last reported at 3.48 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 94.84% year-over-year to 3.48 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17.24 (up 95.15% YoY) and the FY2025 annual result came in at 119.22, down 8.1% from the prior year.
- Interest Coverage Ratio advanced to 3.48 in Q1 2026, from 125.82 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 3.48 in Q1 2026 to a low of 126.23 in Q4 2022.
- A 5-year average of 40.14 and a median of 19.14 in 2022 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio slumped 2007.75% — and 2026, when it soared 94.84%.
- Tracing INTI's Interest Coverage Ratio over 5 years: stood at 126.23 in 2022, then soared by 89.23% to 13.6 in 2023, then tumbled by 229.12% to 44.75 in 2024, then plunged by 181.14% to 125.82 in 2025, then jumped by 97.24% to 3.48 in 2026.
- The last three Interest Coverage Ratio figures came in at 3.48 (Q1 2026), 125.82 (Q4 2025), and 74.12 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 1.42 |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.48 |
| Dec 31, 2025 | -125.82 |
| Sep 30, 2025 | -74.12 |
| Jun 30, 2025 | -21.02 |
| Mar 31, 2025 | -67.46 |
| Dec 31, 2024 | -44.75 |
| Sep 30, 2024 | -8.13 |
| Jun 30, 2024 | -8.36 |
| Mar 31, 2024 | -15.50 |
| Dec 31, 2023 | -13.60 |
| Sep 30, 2023 | -75.95 |
| Mar 31, 2023 | -20.99 |
| Dec 31, 2022 | -126.23 |
| Sep 30, 2022 | -9.08 |
| Jun 30, 2022 | -10.47 |
| Mar 31, 2022 | -17.28 |
| Dec 31, 2021 | -5.99 |
| Sep 30, 2021 | -13.79 |
| Jun 30, 2021 | -17.66 |
| Mar 31, 2021 | -99.56 |